CNS Specific Antisense Oligonucleotide Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-01-23　·　151 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 3,200 Mn
2033 年預估規模: USD 6,100 Mn
年複合成長率 CAGR: 9.8%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-01-23頁數 151報告編號 CMI2477

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

CNS Specific Antisense Oligonucleotide Market, By Drug (Approved and Pipeline), By Indication (Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy, Spinal Muscular Atrophy, and Huntingtons Disease), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

報告摘要

Antisense oligonucleotides are synthetic strings of nucleic acid, which reduce expression of messenger RNA (m-RNA). The function performed by interference with pre m- RNA splicing are restoration of protein and modification of protein. Antisense oligonucleotide is a new approach to treat several neurodegenerative disorders to prevent disease onset or stop disease development. Market Dynamics Increasing prevalence of neurodegenerative disease is a major factor driving CNS specific antisense oligonucleotide market growth. According to fact sheet from Alzheimer Association, an estimated around 5.7 million Americans were diagnosed with Alzheimer's dementia in 2018. Moreover, rich product pipeline for the treatment of CNS disorders and rare diseases associated with it is expected to boost the market growth. For instance, in December 2018, Biogen and Ionis Pharmaceuticals product IONIS-SOD1Rx (BIIB067) cleared Phase 1 clinical trial and is expected to be launched by 2020. Key features of the study • This report provides in-depth analysis of the CNS specific antisense oligonucleotide market and provides market size (USD million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players • It profiles key players in the global CNS specific antisense oligonucleotide market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans • Key companies covered as a part of this study include, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Stroke Therapeutic Inc., Dynacure, ProQR Therapeutics N.V., Q-STATE BIOSCIENCES, INC. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics • The global CNS specific antisense oligonucleotide market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the CNS specific antisense oligonucleotide market Market Segmentation • Drug Insights (Revenue, USD Mn, 2026 - 2033) o Approved o Pipeline • Indication Insights (Revenue, USD Mn, 2026 - 2033) o Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy o Spinal Muscular Atrophy o Huntington’s Disease • Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033) o Hospital Pharmacy o Retail Pharmacy o Online Pharmacy • Regional Insights (Revenue, USD Mn, 2026 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC  Israel  Rest of Middle East o Africa  North Africa  Central Africa  South Africa • Key Players Insights o Alnylam Pharmaceuticals Inc. o Sarepta Therapeutics Inc. o Biogen Inc. o Ionis Pharmaceuticals Inc. o Wave Life Sciences Ltd. o Stroke Therapeutic Inc. o Dynacure o ProQR Therapeutics N.V. o Q-STATE BIOSCIENCES, INC.

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Overview o Report Description  Market Definition and Scope o Executive Summary  Global CNS Specific Antisense Oligonucleotide Market, By Drug  Global CNS Specific Antisense Oligonucleotide Market, By Indication  Global CNS Specific Antisense Oligonucleotide Market, By Distribution Channel  Global CNS Specific Antisense Oligonucleotide Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Key Developments o Industry Trend 4. Global CNS Specific Antisense Oligonucleotide Market, By Drug, 2020-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Approved  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) o Pipeline  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) 5. Global CNS Specific Antisense Oligonucleotide Market, By Indication, 2020-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) o Spinal Muscular Atrophy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) o Huntington’s Disease  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) 6. Global CNS Specific Antisense Oligonucleotide Market, By Distribution Channel Type, 2020-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Hospital Pharmacy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) o Retail Pharmacy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) o Online Pharmacy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn) 7. Global CNS Specific Antisense Oligonucleotide Market, By Region, 2020 - 2033, Value (USD Mn) o Introduction  Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Mn)  Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Mn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Drug, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2020 - 2033, Value (USD Mn) o South Africa o North Africa o Central Africa 8. Competitive Landscape o Alnylam Pharmaceuticals Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Sarepta Therapeutics Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Biogen Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Ionis Pharmaceuticals Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Wave Life Sciences Ltd.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Stroke Therapeutic Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Dynacure  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o ProQR Therapeutics N.V.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Q-STATE BIOSCIENCES, INC.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 9. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 10. References and Research Methodology o References o Research Methodology o About us

提及公司

Alnylam Pharmaceuticals Inc.Sarepta Therapeutics Inc.Biogen Inc.Ionis Pharmaceuticals Inc.Wave Life Sciences Ltd.Stroke Therapeutic Inc.DynacureProQR Therapeutics N.V.Q-STATE BIOSCIENCES, INC.

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們